Frederic Jaisser, MD, PhD got a permanent position as Director of Research at the National Institute of Health and Medical Research (INSERM) in 1996. Dr. Jaisser received his medical training and degrees from the Reims Medical School France and was qualified as Nephrologist in 1990. In 2003, he joined the Collège de France in Paris as an independent INSERM team and since 2009 he manage a team of the INSERM Unit U1138, at the Cordeliers Research Centre, Paris. He is Deputy Director of the Cordeliers Research Centre and Head of the “Pathophysiology, Metabolism” Department. Between 2010-2015, he was Scientific Delegate of the Pathophysiology Committee of the French National Research Agency. In 2020 he has been appointed as President of the ECOS French-South America exchange program and is particularly in charge of the Health projects between France and South America.
The aim of his studies is to improve the understanding of the pathophysiological roles and signaling pathways whereby the hormone aldosterone promotes pathologies in various organs including the kidney and the cardiovascular system but also eye skin and liver. His work combines cellular and molecular approaches, animal physiology, pharmacological studies and has implications in human diseases. His interest includes translational research aimed to identify and validate biomarkers of Mineralocorticoid Receptor activation in cardiovascular and kidney diseases and novel therapeutic use of MR antagonists.
In the past years he focused his research on the impact of various MR antagonists, including the non-steroidal MRAs finerenone on the cardiovascular impact of chronic kidney disease and/or progression of renal failure. He uncovered in collaboration with experts of skin or eye diseases a major benefit of topical or systemic MR antagonism in skin wound healing delay associated to dermocorticoids and diabetes or in age-related macular degeneration or diabetic retinopathy. He identified novel signaling pathways such as the Neutrophil Gelatinase-Associated Lipocalin as a major underlying mechanism in fibrotic and inflammatory consequences of MR activation in renal and cardiovascular diseases.
Faiez Zannad is a MD, cardiologist, and PhD in clinical pharmacology. He trained at the Université de Lorraine, Nancy, France, at Université Claude Bernard, Lyon, France, and at Oxford MRC, UK. He is Professor Emeritus of Therapeutics and Past Director of the Inserm Clinical Investigation Center at the Université of Lorraine, Nancy, France.
He has significantly contributed to building the evidence supporting modern heart failure (HF) therapy, including mineralocorticoid receptor antagonists, beta-blockers, and anticoagulants. Dr. Zannad is Past Chairman of the French Society of Hypertension, and of the European Society of Cardiology (ESC) Working Group on Pharmacology and Drug Therapy. He is founder of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, a think tank meeting dedicated to the science of clinical trials, with meetings in Paris, Washington DC, in Asia, and the Middle East. Dr. Zannad published more than 1000 peer-reviewed papers. He received the 2014 European Society of Hypertension Paul Milliez Award, the 2017 Lifetime Achievement Award from the ESC-HFA, and the 2022 HFSA international Honorary fellowship. In 2019, he served as Eugene Braunwald Scholar at Harvard Medical School.